TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04046614
Drug: nintedanib-nivolumab combination therapy
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease.
Study: NCT00443573
Drug: recombinant nematode anticoagulant protein c2 (rNAPc2)
Normalized name: recombinant nematode anticoagulant protein c2 (rNAPc2)
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating dose administered 2x/week sq.
Study: NCT01891136
Drug: Peanut protein
Normalized name: peanut protein
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
Study: NCT00026156
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00026156
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181673
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Study: NCT00833664
Drug: Terbinafine HCl 250mg tablets
Normalized name: terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 250 mg
Study: NCT02974270
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01808092
Drug: ceftazidim-avibactam (CAZ-AVI, experimental product)
Normalized name: avibactam
DrugBank: Avibactam (DB09060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2000mg ceftazidime plus 500mg avibactam
Study: NCT01808092
Drug: meropenem (active comparator)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg of Meropenem
Study: NCT04469998
Drug: AXR-270 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AXR-270 Topical Eyelid Cream
Study: NCT04469998
Drug: AXR-270 High Dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXR-270 Topical Eyelid Cream
Study: NCT00004646
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02657473
Drug: tobramycin inhalation solution
Normalized name: Tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01188759
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks.
Study: NCT01715012
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline is applied daily by spray to burn wound and skin graft donor site
Study: NCT01188759
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.
Study: NCT01429025
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01429025
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PO
Study: NCT00476008
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
Study: NCT01170247
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Ketamine (100 mg/mL)
Study: NCT01170247
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Ketamine
Study: NCT01788358
Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
Study: NCT01788358
Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
Study: NCT01788358
Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
Study: NCT01788358
Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
Study: NCT00921167
Drug: Bevacizumab/Irinotecan
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
Study: NCT00539006
Drug: FFNS
Normalized name: Fluticasone Furoate Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluticasone furoate nasal spray
Study: NCT00320801
Drug: Buprenorphine transdermal patch
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
Study: NCT00320801
Drug: Buprenorphine transdermal patch
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Study: NCT01539044
Drug: Neostigmine, atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
Study: NCT01539044
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
Study: NCT00116298
Drug: stavudine, efavirenz, lamivudine
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00347373
Drug: Tonalin Conjugated linoleic acid (dietary supplement)
Normalized name: linoleic acids, conjugated
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03664596
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid in the form of 250 mg capsule.
Study: NCT00296296
Drug: Cyclosporin
Normalized name: Cyclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustment to pre-established targets
Study: NCT00296296
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose adjustment to pre-established targets
Study: NCT02934503
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2
Study: NCT02934503
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6
Study: NCT02934503
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
Study: NCT00555061
Drug: Retapamulin Ointment, 1%
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% Ointment
Study: NCT00951613
Drug: NK012
Normalized name: Nanoparticle Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
Study: NCT00306319
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03848182
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered on days 1, 8, 15 every 28 days
Study: NCT00373893
Drug: Lidoderm Patch
Normalized name: lidocaine Medicated Patch [Lidoderm]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03000439
Drug: In open-label phase: treatment with tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with investigational drug
Study: NCT03000439
Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with investigational drug or placebo
Study: NCT02267993
Drug: recombinant human thrombopoietin
Normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
Study: NCT03926611
Drug: LOU064 Arm 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Study: NCT03926611
Drug: LOU064 Arm 2
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Study: NCT03926611
Drug: LOU064 Arm 3
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Study: NCT03926611
Drug: LOU064 Arm 4
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg bid of LOU064 orally, twice daily from Day 1 to 85
Study: NCT03926611
Drug: LOU064 Arm 5
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg bid of LOU064 orally, twice daily from Day 1 to 85
Study: NCT03926611
Drug: LOU064 Arm 6
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg bid of LOU064 orally, twice daily from Day 1 to 85
Study: NCT00549068
Drug: Risedronate Sodium (Actonel)
Normalized name: risedronate sodium Oral Tablet [Actonel]
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00389987
Drug: Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01146327
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
Study: NCT01146327
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
Study: NCT01146327
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
Study: NCT01146327
Drug: PF-04620110
Normalized name: PF-04620110
DrugBank: PF-04620110 (DB14887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
Study: NCT01421472
Drug: MM-121
Normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
Study: NCT01421472
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
Study: NCT00207064
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible doses according to the clinical condition
Study: NCT01652482
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT01652482
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
Study: NCT01652482
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT01623713
Drug: iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
Study: NCT01623713
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
Study: NCT00753246
Drug: nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody
Study: NCT00475306
Drug: metoclopramide 10 mg
Normalized name: metoclopramide 10 MG
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an anti-emetic medication
Study: NCT00475306
Drug: Diphenhydramine 25 mg
Normalized name: diphenhydrAMINE 25 mg oral tablet
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used for prophylaxis against akathisia
Study: NCT00475306
Drug: Metoclopramide 20 mg
Normalized name: metoclopramide 20 MG
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 20 mg
Study: NCT01042041
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00544713
Drug: Carboxymethylcellulose and Glycerin based artificial tear
Normalized name: carboxymethylcellulose / glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Study: NCT01042041
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via transarterial/hepatic chemoembolization
Study: NCT01042041
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via transarterial/hepatic chemoembolization
Study: NCT00544713
Drug: Carboxymethylcellulose
Normalized name: Carboxymethylcellulose
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Study: NCT02353572
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02353572
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00641641
Drug: Tenofovir + emtricitabine + raltegravir.
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
Study: NCT01290913
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab is an antibody that helps decrease allergic responses in the body
Study: NCT02353572
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02726997
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02726997
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03284385
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03486626
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
Study: NCT00522938
Drug: CHR-2797 (tosedostat)
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
Study: NCT00522938
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
Study: NCT00170378
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02117622
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
Study: NCT02150434
Drug: Compressed air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compressed air delivered at a fixed flow of 2 L/min
Study: NCT02150434
Drug: Oxygen constant flow
Normalized name: constant albicans extract
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxygen delivered at a fixed flow of 2L/min
Study: NCT02536417
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine if placebo effect plays a part in preventing the development of delirium
Study: NCT01785992
Drug: Irosustat
Normalized name: Irosustat
DrugBank: Irosustat (DB02292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
Study: NCT01723371
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
Study: NCT00824993
Drug: Vitamin Supplements
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months
Study: NCT04228029
Drug: Intralesional Steroid Injection
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone acetonide 8 mg/mL